<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Cryptococcus gattii infection: Clinical features and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Cryptococcus gattii infection: Clinical features and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Cryptococcus gattii infection: Clinical features and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sharon Chen, PhD, MBBS, FRACP, FRCPA
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Tania C Sorrell, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carol A Kauffman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Milana Bogorodskaya, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 25, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H12417153">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Cryptococcus gattii
         </em>
         has emerged as an important fungal pathogen. Infection manifests most often as potentially fatal meningoencephalitis and/or pulmonary disease. The emergence of clusters of cryptococcosis due to
         <em>
          C. gattii
         </em>
         in British Columbia, Canada in 1999, with subsequent spread to the United States Pacific Northwest, challenged our understanding of this disease [
         <a href="#rid1">
          1,2
         </a>
         ]. With more robust microbial testing, we now appreciate its presence as an important pathogen in North America, especially in western regions.
         <em>
          C. gattii
         </em>
         infection had previously been detected infrequently and was thought to be largely restricted to tropical and subtropical regions, including Australia and Papua New Guinea. It is now clear that sporadic cases occur in various regions around the world.
        </p>
        <p>
         The clinical manifestations, complications, and diagnosis of
         <em>
          C. gattii
         </em>
         infection will be reviewed here. The microbiology, epidemiology, pathogenesis, and treatment of
         <em>
          C. gattii
         </em>
         infection are discussed separately;
         <em>
          Cryptococcus neoformans
         </em>
         infection is also reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/16624.html" rel="external">
          "Cryptococcus gattii infection: Microbiology, epidemiology, and pathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90020.html" rel="external">
          "Cryptococcus gattii infection: Treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2448.html" rel="external">
          "Microbiology and epidemiology of Cryptococcus neoformans infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3757.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of Cryptococcus neoformans meningoencephalitis in patients with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2447.html" rel="external">
          "Clinical manifestations and diagnosis of Cryptococcus neoformans meningoencephalitis in patients without HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2421.html" rel="external">
          "Cryptococcus neoformans infection outside the central nervous system"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2443.html" rel="external">
          "Cryptococcus neoformans: Treatment of meningoencephalitis and disseminated infection in patients without HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12417160">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H12417364">
         <span class="h2">
          Incubation period
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incubation period of
         <em>
          C. gattii
         </em>
         infection in humans is uncertain. A study of seven travelers to Vancouver Island, British Columbia, revealed a median time to clinical presentation of six to seven months (range 2 to 11 months) [
         <a href="#rid3">
          3
         </a>
         ]. A subsequent report of a traveler to British Columbia suggested a shorter incubation of six weeks [
         <a href="#rid4">
          4
         </a>
         ], whereas other reports have described patients who developed infection 13 months and 36 months after exposure, respectively [
         <a href="#rid5">
          5,6
         </a>
         ]. The proportion of
         <em>
          C. gattii
         </em>
         disease representing acute infection versus reactivation of latent infection remains unknown; however, most reported cases of
         <em>
          C. gattii
         </em>
         infection appear to be primary infections.
        </p>
        <p class="headingAnchor" id="H12417182">
         <span class="h2">
          Clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          C. gattii
         </em>
         infection often presents as an indolent illness and most commonly involves the central nervous system (CNS), the lungs, or both. Neurologic infection is more common in cases of
         <em>
          C. gattii
         </em>
         infection that occur in endemic areas (eg, Australia), compared with the Vancouver outbreak setting, where pulmonary manifestations were more frequent. As with
         <em>
          C. neoformans,
         </em>
         HIV-infected patients with
         <em>
          C. gattii
         </em>
         infection overwhelmingly present with meningoencephalitis (up to 97 percent of cases) [
         <a href="#rid7">
          7,8
         </a>
         ]. Systemic features including fever, chills, and weight loss were reported in 17 to 47 percent of patients in the North American Pacific Northwest outbreak [
         <a href="#rid9">
          9-11
         </a>
         ]. Fever was reported in 54 percent of HIV-infected patients with
         <em>
          C. gattii
         </em>
         infection in South Africa [
         <a href="#rid7">
          7
         </a>
         ] and in 37 percent of patients in Colombia [
         <a href="#rid12">
          12
         </a>
         ], but was uncommon (10 percent) in patients with
         <em>
          C. gattii
         </em>
         infection in Australia [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H558179943">
         <span class="h3">
          Neurologic features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Headache and neck stiffness are common neurologic symptoms at diagnosis. Other neurologic deficits that may be present, or evolve during the course of illness, include seizures, cranial nerve deficits, cerebellar abnormalities, focal limb weakness, and abnormal mentation (eg, confusion and personality change) [
         <a href="#rid12">
          12-17
         </a>
         ].
        </p>
        <p>
         Among 47 patients with culture-confirmed
         <em>
          C. gattii
         </em>
         infection in Australia and New Zealand in the 1990s, meningitis and/or brain involvement occurred in 30 patients (64 percent) [
         <a href="#rid18">
          18
         </a>
         ]. With wider availability of cerebral computed tomography (CT) and magnetic resonance imaging (MRI), additional data revealed CNS involvement in 73 of 86
         <em>
          C. gattii
         </em>
         -infected patients (85 percent: 76 percent with meningoencephalitis and 52 percent with brain infection, including cryptococcomas) [
         <a href="#rid13">
          13,19
         </a>
         ]. In Colombian patients with
         <em>
          C. gattii
         </em>
         infection, more than 80 percent had neurological disease [
         <a href="#rid12">
          12
         </a>
         ]. By contrast, among patients affected by the outbreak in British Columbia, Canada, and the United States Pacific Northwest, CNS disease was estimated to occur in approximately 31 to 49 percent of cases [
         <a href="#rid10">
          10,11,20,21
         </a>
         ]. More recently, in an analysis of 257 patients from the United States and Australia, CNS infection was present in 50 percent of cases [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H558180097">
         <span class="h3">
          Papilledema
         </span>
         <span class="headingEndMark">
          —
         </span>
         When papilledema is present, most commonly, optic disc swelling is seen with loss of definition of the disc margins [
         <a href="#rid16">
          16
         </a>
         ]. Hemorrhagic changes around the disc accompanied by loss of visual acuity occur in severe cases. (See
         <a class="local">
          'Complications'
         </a>
         below.)
        </p>
        <p>
         Papilledema was observed in 15 to 53 percent of cases of
         <em>
          C. gattii
         </em>
         infection in Australia and Papua New Guinea [
         <a href="#rid13">
          13,16
         </a>
         ]. In the United States Pacific Northwest outbreak, seizures and papilledema occurred in only 8 and 6 percent of cases, respectively [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H558180215">
         <span class="h3">
          Pulmonary features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cough, dyspnea, and chest pain are the most common symptoms of lung infection, but pulmonary nodules or cryptococcomas observed on chest radiograph can also be asymptomatic [
         <a href="#rid20">
          20
         </a>
         ]. Very large lesions are typical of disease due to
         <em>
          C. gattii
         </em>
         [
         <a href="#rid19">
          19,22
         </a>
         ]; in at least one case, involvement of the right upper lobe presented with Pancoast syndrome mimicking lung malignancy [
         <a href="#rid23">
          23
         </a>
         ]. (See
         <a class="local">
          'Chest imaging'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/4605.html" rel="external">
          "Superior pulmonary sulcus (Pancoast) tumors", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
         Lung disease predominated in the outbreak of
         <em>
          C. gattii
         </em>
         infection in British Columbia, Canada, and the United States Pacific Northwest [
         <a href="#rid9">
          9-11,20,21
         </a>
         ]. Among 218 patients with
         <em>
          C. gattii
         </em>
         infection as part of the outbreak in British Columbia, 189 (87 percent) presented with a respiratory syndrome, 22 of whom (10 percent) also had CNS disease [
         <a href="#rid20">
          20
         </a>
         ]. Isolated lung infection was present in 69 percent of patients [
         <a href="#rid11">
          11
         </a>
         ]. Of patients with
         <em>
          C. gattii
         </em>
         infection in the outbreak in the United States Pacific Northwest, 31 of 57 (54 percent) presented with pneumonia, and 20 of 61 (33 percent) had lung cryptococcomas [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         Lung infection was also common in Australia (in 63 to 67 percent of cases), but occurred mostly in conjunction with CNS disease (in 81 percent of cases) [
         <a href="#rid13">
          13,18,24
         </a>
         ]. In Colombia, of the 45 patients with
         <em>
          C. gattii
         </em>
         infection, only 6.7 percent had pulmonary cryptococcosis [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H558180471">
         <span class="h3">
          Other features
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to the brain, eyes, and lungs,
         <em>
          C. gattii
         </em>
         can also involve the skin, soft tissues  (
         <a class="graphic graphic_diagnosticimage graphicRef90071" href="/z/d/graphic/90071.html" rel="external">
          image 1
         </a>
         ), bones, joints, bone marrow, larynx, and lymph nodes, and can be found in blood [
         <a href="#rid13">
          13,14,17,25-28
         </a>
         ]. Intra-abdominal cryptococcosis is rare [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         Such sites are more often culture positive in immunocompromised hosts and hence only occasionally involved in patients with
         <em>
          C. gattii
         </em>
         disease, most of whom are immunocompetent [
         <a href="#rid14">
          14
         </a>
         ]. However, in one study, the likelihood of the involvement of blood, CNS, lungs, and other body sites was independent of host immune status [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         Cutaneous infections can occur either in conjunction with lung and CNS infection or as primary skin disease [
         <a href="#rid25">
          25,26,29
         </a>
         ]. Lesions typically affect the face and neck as papules, pustules, ulcers, subcutaneous masses, or cellulitis.
        </p>
        <p class="headingAnchor" id="H211625782">
         <span class="h2">
          Comparison of C. gattii and C. neoformans infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain clinical features of
         <em>
          C. gattii
         </em>
         infection are different from those noted with
         <em>
          C. neoformans
         </em>
         infection. As an example, pulmonary infection (but not CNS involvement) is much more likely to occur in
         <em>
          C. gattii
         </em>
         infection when compared with
         <em>
          C. neoformans
         </em>
         disease [
         <a href="#rid17">
          17
         </a>
         ].
         <em>
          C. gattii
         </em>
         is also significantly more likely than
         <em>
          C. neoformans
         </em>
         to cause large mass lesions (cryptococcomas) of the lungs and/or the brain [
         <a href="#rid18">
          18,24,30,31
         </a>
         ]. Such large mass lesions, especially when occurring as single lesions, can mimic neoplastic disease or pyogenic abscesses  (
         <a class="graphic graphic_diagnosticimage graphicRef90023" href="/z/d/graphic/90023.html" rel="external">
          image 2
         </a>
         ).
        </p>
        <p>
         In addition to differences in clinical manifestations between
         <em>
          C. gattii
         </em>
         and
         <em>
          C. neoformans
         </em>
         infection, there are also differences in host factors. In the nonoutbreak setting in countries endemic for this fungus,
         <em>
          C. gattii
         </em>
         infection largely affects immunocompetent patients rather than immunocompromised patients; the opposite is true for
         <em>
          C. neoformans
         </em>
         infection. (See
         <a class="medical medical_review" href="/z/d/html/16624.html" rel="external">
          "Cryptococcus gattii infection: Microbiology, epidemiology, and pathogenesis", section on 'Hosts'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12417189">
         <span class="h2">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Elevated intracranial pressure (ICP), defined as cerebrospinal fluid (CSF) pressure &gt;20 cm H
         <sub>
          2
         </sub>
         0, is a common complication of meningitis due to
         <em>
          C. gattii
         </em>
         (occurring in 29 to 77.8 percent of cases [
         <a href="#rid11">
          11,12
         </a>
         ]), as it is for
         <em>
          C. neoformans
         </em>
         (occurring in 30 to 75 percent of cases) [
         <a href="#rid13">
          13,16,32,33
         </a>
         ]. Early raised ICP was a poor prognostic indicator in studies of
         <em>
          C. gattii
         </em>
         in Papua New Guinea [
         <a href="#rid16">
          16,34
         </a>
         ]. In a study from Australia, elevated ICP was associated with abnormal neurologic findings at presentation and neurologic sequelae and/or death at 12 months [
         <a href="#rid35">
          35
         </a>
         ]. These finding have been supported by clinical experience and by an illustrative case report from the United States, where adverse outcomes were seen in a patient who had severe
         <em>
          C. gattii
         </em>
         CNS disease with an initial CSF pressure &gt;60 cm H
         <sub>
          2
         </sub>
         O [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         Manifestations of increased ICP include severe headache, papilledema, vision loss, hearing loss, other neurologic deficits, and death, presumably from brain ischemia [
         <a href="#rid16">
          16,33,35
         </a>
         ]. Cryptococcomas due to
         <em>
          C. gattii
         </em>
         have caused or contributed to raised ICP or obstructive hydrocephalus via a mass effect [
         <a href="#rid15">
          15,37
         </a>
         ]. In one study, 25 percent of patients with
         <em>
          C. gattii
         </em>
         infection and hydrocephalus had "silent" meningitis, presenting with features of hydrocephalus, dilated ventricles on brain CT scan, and unexpected findings of meningitis on CSF examination [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="local">
          'Brain imaging'
         </a>
         below.)
        </p>
        <p>
         Symptomatic hydrocephalus, ataxia, and deteriorating mental status in association with meningitis generally respond well to relief of pressure by insertion of a CSF shunt [
         <a href="#rid15">
          15,24,37
         </a>
         ]. Factors that predispose patients with
         <em>
          C. gattii
         </em>
         meningitis to develop hydrocephalus remain unclear.
        </p>
        <p>
         Compared with
         <em>
          C. neoformans
         </em>
         infection, papilledema, seizures, focal neurologic deficits, and severe neurologic sequelae have been reported more frequently in
         <em>
          C. gattii
         </em>
         infections [
         <a href="#rid15">
          15,24
         </a>
         ]. Ocular complications of
         <em>
          C. gattii
         </em>
         infection include papilledema, visual field defects, extraocular muscle paresis, impaired pupillary and accommodative function, multifocal choroiditis, endophthalmitis, and optic atrophy [
         <a href="#rid15">
          15,16
         </a>
         ]. Blindness is a debilitating sequela, thought to result from invasion of the optic nerve by cryptococci, effects of raised ICP, or from local arachnoiditis, leading to nerve infarction and cryptococcal infiltration of the choroid [
         <a href="#rid33">
          33,38,39
         </a>
         ]. High rates (&gt;50 percent) of visual loss have been noted in Papua New Guinea [
         <a href="#rid34">
          34
         </a>
         ], but lower rates have been observed in other endemic areas [
         <a href="#rid13">
          13,17,24,35
         </a>
         ]. An immune reconstitution inflammatory syndrome (IRIS)-like syndrome, which may affect visual function, is discussed below.
        </p>
        <p class="headingAnchor" id="H571890489">
         <span class="h3">
          IRIS-like syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immune reconstitution inflammatory syndrome (IRIS)-like disease has been described uncommonly during treatment of
         <em>
          C. gattii
         </em>
         infection in immunocompetent patients [
         <a href="#rid13">
          13,17,40-42
         </a>
         ]. The mechanism is thought to be due to a switch following initiation of antifungal therapy from a predominantly Th2 immune response (anti-inflammatory) to a Th1 or proinflammatory response [
         <a href="#rid43">
          43,44
         </a>
         ].
        </p>
        <p>
         Patients develop clinical deterioration, including neurologic deficits such as visual impairment associated with one or more inflammatory mass lesions, meningeal enhancement, hydrocephalus, and/or increased inflammation in the CSF during the course of successful antifungal therapy. IRIS-like changes may occur late in disease and account for symptomatic relapse after an apparently successful antifungal induction course [
         <a href="#rid40">
          40,41,45
         </a>
         ].
        </p>
        <p>
         In an observational study that evaluated the therapy and long-term outcomes of 86 patients with
         <em>
          C. gattii
         </em>
         infection in Australia, an IRIS-like syndrome developed 6 weeks to 12 months after starting antifungal therapy in eight patients who presented with new or enlarging brain lesions; two of these patients were immunocompromised and one was pregnant [
         <a href="#rid35">
          35
         </a>
         ]; the estimated frequency of IRIS in a recent retrospective multicentre study was 7.1 percent [
         <a href="#rid17">
          17
         </a>
         ]. Risk factors for the development of an IRIS-like syndrome included female sex, brain involvement at presentation, and higher median CD4 count; glucocorticoids reduced cryptococcoma-associated edema.
        </p>
        <p>
         The management of the IRIS-like syndrome is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/90020.html" rel="external">
          "Cryptococcus gattii infection: Treatment", section on 'IRIS-like syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12417196">
         <span class="h1">
          IMAGING
         </span>
        </p>
        <p class="headingAnchor" id="H12417393">
         <span class="h2">
          Chest imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Imaging of the chest may provide the first clues to disease, including the finding of incidental disease. In endemic areas such as Australia, the predominant pulmonary manifestations have been circumscribed cryptococcomas  (
         <a class="graphic graphic_diagnosticimage graphicRef90023" href="/z/d/graphic/90023.html" rel="external">
          image 2
         </a>
         ), both in patients with lung infection only (83 percent) and in those with combined lung and central nervous system disease (77 percent) [
         <a href="#rid13">
          13,18,19
         </a>
         ]. In the British Columbia, Canada outbreak, an initial report found that 75 percent of patients had pulmonary nodules [
         <a href="#rid20">
          20
         </a>
         ]. In subsequent publications of the same outbreak, pulmonary cryptococcomas, either single or multiple, were present in 66 percent of patients [
         <a href="#rid11">
          11
         </a>
         ]. In a Chinese study, pulmonary nodules/masses were present in 65 (90.3 percent) of 72 patients [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         Cryptococcomas range from 1 to 7 cm diameter with smooth or ill-defined edges and have no particular lobar predilection  (
         <a class="graphic graphic_diagnosticimage graphicRef90023" href="/z/d/graphic/90023.html" rel="external">
          image 2
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef90471" href="/z/d/graphic/90471.html" rel="external">
          image 3
         </a>
         ) [
         <a href="#rid19">
          19,30,47
         </a>
         ]. Alveolar and interstitial pulmonary infiltrates account for 14 to 17 percent of chest abnormalities [
         <a href="#rid17">
          17
         </a>
         ]; these findings have occurred more frequently (26 to 70 percent) in immunocompromised hosts [
         <a href="#rid17">
          17,18,20,48
         </a>
         ], but can also be seen in immunocompetent patients with lung cryptococcosis [
         <a href="#rid49">
          49
         </a>
         ]. Pleural effusions, cavitary lesions, and lymphadenopathy are less common.
        </p>
        <p>
         Computed tomography (CT) scans are more sensitive than chest radiographs for detecting abnormalities. Following treatment, lesions can persist for a prolonged period, despite conversion of biopsy specimens to culture negative.
        </p>
        <p>
         It is worthy of mention that lung lesions, such as large cryptococcomas, can commonly masquerade as neoplastic lesions [
         <a href="#rid23">
          23
         </a>
         ]. In the Vancouver outbreak, more than 42 percent of patients had a provisional diagnosis of malignancy until diagnosis of
         <em>
          C. gattii
         </em>
         infection was made [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12417204">
         <span class="h2">
          Brain imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intracranial disease manifests on CT or magnetic resonance imaging (MRI) as single or multiple cryptococcomas, with or without contrast enhancement and edema, and hydrocephalus  (
         <a class="graphic graphic_diagnosticimage graphicRef90072" href="/z/d/graphic/90072.html" rel="external">
          image 4
         </a>
         ). The most common sites of involvement included the basal ganglia, thalamus, and cerebellum [
         <a href="#rid18">
          18
         </a>
         ]. MRI is more sensitive than CT scanning for detecting small mass lesions and showing basilar meningeal enhancement after injection of gadolinium [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         In one study, cryptococcomas were observed on cranial CT scans in 33 to 58 percent of cases [
         <a href="#rid18">
          18
         </a>
         ], and obstructive hydrocephalus has been reported in 17 to 36 percent of cases [
         <a href="#rid15">
          15,17,18,24
         </a>
         ], but the frequency of these findings varies [
         <a href="#rid11">
          11
         </a>
         ]. In addition, some patients with symptoms of raised intracranial pressure (ICP) may have imaging findings on CT that do not show dilated ventricles ("frozen brain") [
         <a href="#rid51">
          51
         </a>
         ]. It is important to note that imaging may also be normal [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12417211">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory diagnosis of
         <em>
          C. gattii
         </em>
         infection is usually straightforward, although many microbiology laboratories in nonendemic areas do not identify
         <em>
          Cryptococcus
         </em>
         to the species level. With the increasing awareness of the differences in clinical manifestations of
         <em>
          C. gattii
         </em>
         infection compared with
         <em>
          C. neoformans
         </em>
         , clinicians should be aware that some laboratories will report "
         <em>
          C. neoformans
         </em>
         " to indicate the species complex, even when the causative organism is
         <em>
          C. gattii
         </em>
         .
        </p>
        <p class="headingAnchor" id="H526557027">
         <span class="h2">
          Approach to diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to diagnosis of
         <em>
          C. gattii
         </em>
         infection is generally similar to that for
         <em>
          C. neoformans
         </em>
         infection, although brain and chest imaging to look for cryptococcomas is more of a priority with
         <em>
          C. gattii
         </em>
         than
         <em>
          C. neoformans
         </em>
         given the propensity of
         <em>
          C. gattii
         </em>
         to cause cryptococcomas. A variety of tests are indicated for evaluating patients with possible
         <em>
          C. gattii
         </em>
         infection, as outlined below.
        </p>
        <p>
         Although
         <em>
          C. gattii
         </em>
         commonly affects people without apparent immunocompromise, evaluation for HIV infection (by HIV antibody testing) and other general causes of immunocompromise (eg, CD4 cell count for idiopathic CD4 lymphopenia, quantitative immunoglobulin subsets) is recommended since up to 50 percent of patients in studies from the outbreak in the Pacific Northwest of North America were immunosuppressed [
         <a href="#rid10">
          10,52
         </a>
         ]. In addition, there is some evidence that such infections may serve as sentinels for underlying immunodeficiency [
         <a href="#rid53">
          53,54
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16624.html" rel="external">
          "Cryptococcus gattii infection: Microbiology, epidemiology, and pathogenesis", section on 'Hosts'
         </a>
         .)
        </p>
        <p>
         The following tests should be performed in patients suspected of having
         <em>
          C. gattii
         </em>
         meningoencephalitis (eg, patients residing in an endemic area or an area affected by an outbreak [eg, the Pacific Northwest region of North America] presenting with a headache with or without neck stiffness and/or fever), pneumonia, or infection of other sites. Even in patients who are found to have infection of a site other than the central nervous system (CNS) and who do not have clinical manifestations suggestive of CNS infection, a lumbar puncture and cerebral imaging are necessary because the presence or absence of CNS disease will affect the choice of therapy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Funduscopic examination
         </strong>
         – All patients should undergo a funduscopic examination to evaluate for papilledema prior to undergoing lumbar puncture. (See
         <a class="local">
          'Clinical features'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5241.html" rel="external">
          "Overview and differential diagnosis of papilledema"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cerebral imaging
         </strong>
         – Some patients will require cerebral imaging with a head computed tomography (CT) scan prior to undergoing lumbar puncture. Patients who do not require a head CT prior to lumbar puncture but who are found to have
         <em>
          C. gattii
         </em>
         infection should have a head CT with contrast subsequently to look for evidence of cryptococcomas. The indications for CT scan prior to lumbar puncture are discussed in detail separately. For patients who present with altered consciousness and/or focal neurologic signs, we suggest brain magnetic resonance imaging (MRI). (See
         <a class="medical medical_review" href="/z/d/html/1287.html" rel="external">
          "Clinical features and diagnosis of acute bacterial meningitis in adults", section on 'Indications for CT scan before LP'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CSF examination
         </strong>
         – In patients in whom meningoencephalitis is suspected, testing for the possible causes of meningitis and/or encephalitis should be undertaken. Cerebrospinal fluid (CSF) cell counts, white blood cell differential, protein, and glucose should be performed in all patients. The choice of specific tests to evaluate for possible etiologies will depend upon various factors, such as host immune status, clinical presentation, geographic location, and season. (See
         <a class="medical medical_review" href="/z/d/html/1287.html" rel="external">
          "Clinical features and diagnosis of acute bacterial meningitis in adults", section on 'Cerebrospinal fluid examination'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1275.html" rel="external">
          "Approach to the patient with chronic meningitis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1275.html" rel="external">
          "Approach to the patient with chronic meningitis", section on 'Diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1296.html" rel="external">
          "Aseptic meningitis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1284.html" rel="external">
          "Viral encephalitis in adults", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Since one of the critical determinants of outcome of cryptococcal meningoencephalitis is control of intracranial pressure (ICP) pressure, CSF opening pressure should always be measured as part of the lumbar puncture procedure. Pressure should be measured regardless of whether there are features on cerebral CT that suggest the presence of raised ICP [
         <a href="#rid32">
          32,33,51,55
         </a>
         ]. The management of raised ICP is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/90020.html" rel="external">
          "Cryptococcus gattii infection: Treatment", section on 'Monitoring during therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If
         <em>
          C. gattii
         </em>
         is suspected, in addition to routine CSF analysis to evaluate for possible causes of meningoencephalitis, CSF should also be sent for cryptococcal antigen testing, India ink stain, and fungal culture. Among these, the cryptococcal antigen test is the most sensitive, but culture provides a definitive diagnosis and differentiates between
         <em>
          C. gattii
         </em>
         and
         <em>
          C. neoformans
         </em>
         (unlike the other diagnostic tests). In patients who have no signs or symptoms of meningoencephalitis but are undergoing lumbar puncture because they have
         <em>
          C. gattii
         </em>
         of the lungs or another non-CNS site, it is appropriate to focus the CSF studies on those used to evaluate for
         <em>
          C. gattii
         </em>
         infection (CSF cell counts and white blood cell differential, protein, glucose, cryptococcal antigen testing, India ink stain, and fungal culture).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serum cryptococcal antigen
         </strong>
         – In addition to the CSF studies discussed above, we also suggest sending serum for cryptococcal antigen testing. In many cases, this test will have been sent prior to CSF analysis. In patients who are found to have a positive serum cryptococcal antigen prior to lumbar puncture, lumbar puncture is still required in order to determine whether CNS infection is present, to measure opening pressure, and to attempt to culture
         <em>
          C. gattii
         </em>
         . (See
         <a class="medical medical_review" href="/z/d/html/90020.html" rel="external">
          "Cryptococcus gattii infection: Treatment", section on 'Monitoring during therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lung imaging
         </strong>
         – In patients suspected of having
         <em>
          C. gattii
         </em>
         infection, we recommend a chest radiograph and, if there is any suspicion of pulmonary involvement, a noncontrast chest CT. In those with evidence of lung involvement, we suggest fungal stain and culture of appropriate specimens (eg, bronchoalveolar lavage [BAL] fluid).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H526557035">
         <span class="h2">
          Diagnostic tests
         </span>
        </p>
        <p class="headingAnchor" id="H12417218">
         <span class="h3">
          Culture and histopathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Almost all cases of
         <em>
          C. gattii
         </em>
         infection can be diagnosed by visualizing or culturing the organism and/or by a positive serum or CSF cryptococcal antigen test [
         <a href="#rid56">
          56
         </a>
         ]. Since cryptococcal antigen detection does not allow identification of the species of
         <em>
          Cryptococcus
         </em>
         , culture is essential for definitive diagnosis. BAL fluid, fine needle aspirates, or lung biopsy sections are the preferred specimens to diagnose lung infection, but sputum may also yield
         <em>
          C. gattii
         </em>
         . Positive sputum cultures are indicative of invasive disease with few exceptions.
        </p>
        <p>
         Since CNS disease is common and may present in an indolent fashion, CSF should always be examined unless there is a contraindication to lumbar puncture. Brain biopsy is sometimes performed when cryptococcomas are present because they can be confused with brain abscesses and tumors. In patients with focal lesions (pulmonary cryptococcomas, mass lesions in soft tissues), aspirates and/or tissue biopsy specimens should be obtained. Blood cultures, when positive, are useful, but the yield of obtaining a positive culture from blood is not known.
        </p>
        <p>
         Either mucicarmine or alcian blue combined with the Fontana-Masson stain is superior to any of these stains alone for visualizing cryptococci in tissue sections [
         <a href="#rid57">
          57
         </a>
         ]. This approach is more specific than methenamine silver and calcofluor white, since it highlights both the cell wall (Fontana-Masson stain) and mucin-positive capsule (mucicarmine/alcian blue). Since the Fontana-Masson stain detects melanin, dual staining has the added advantage of being able to distinguish rare capsule-deficient strains.
        </p>
        <p>
         India ink staining of CSF is valuable for rapid (&lt;5 minutes) detection of encapsulated cryptococci (5 to 7 micron diameter) as a halo against a black background. CSF India ink was positive in 70 percent of patients with
         <em>
          C. gattii
         </em>
         meningitis in Papua New Guinea [
         <a href="#rid16">
          16
         </a>
         ] and almost 95 percent of cases in Australia [
         <a href="#rid13">
          13
         </a>
         ]. Although the diagnostic sensitivity of India ink staining for
         <em>
          C. neoformans
         </em>
         is reportedly lower in HIV-negative patients than in those with AIDS [
         <a href="#rid58">
          58
         </a>
         ], this has not been observed for
         <em>
          C. gattii
         </em>
         .
        </p>
        <p>
         Clinical specimens may be plated onto selective media for
         <em>
          Cryptococcus
         </em>
         as well as on standard bacteriology agar (on which
         <em>
          Cryptococcus
         </em>
         spp will also grow). Methods are variable in different centers, and some laboratories (even those in areas affected by the ongoing outbreak in the Pacific Northwest of North America) do not identify the organisms to the species level. Use of canavanine glycine-bromothymol blue (CGB) agar is recommended and is sufficient for distinguishing between
         <em>
          C. gattii
         </em>
         and
         <em>
          C. neoformans
         </em>
         ;
         <em>
          C. gattii
         </em>
         colonies will turn CGB agar blue, whereas
         <em>
          C. neoformans
         </em>
         colonies will not change the color of the agar from its original yellow-green [
         <a href="#rid2">
          2,59
         </a>
         ].
        </p>
        <p>
         Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is increasingly used to identify and distinguish between
         <em>
          C. neoformans
         </em>
         and
         <em>
          C. gattii.
         </em>
         If commercial spectral databases are used alone, distinguishing between the two species may not be possible. Often, supplementation with in-house-generated spectra of both species or use of a research database is required [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12417225">
         <span class="h3">
          Cryptococcal antigen
         </span>
         <span class="headingEndMark">
          —
         </span>
         Detection of cryptococcal polysaccharide antigen in body fluids by latex agglutination or enzyme-linked immunosorbent assay (ELISA) methods has high sensitivity and specificity for the diagnosis of
         <em>
          C. gattii
         </em>
         infection. The sensitivity of serum cryptococcal antigen testing is 94 to 100 percent for CNS disease and 90 percent for lung disease; the sensitivity of CSF cryptococcal antigen testing is 87 to 100 percent, and specificity is 100 percent [
         <a href="#rid7">
          7,13,61
         </a>
         ]. False-negative results are uncommon but may be due to a prozone effect (in which the amount of antigen in the sample is in excess of the amount of antibody in the assay; this can be overcome by sample dilution) or occasionally from low organism burden or rare capsule-deficient strains. False-positive tests are also uncommon [
         <a href="#rid59">
          59
         </a>
         ]. Agreement between the two most commonly used commercial test formats, latex agglutination and enzyme-linked immunoassays (EIAs), is excellent (92 to 98 percent) [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
         Test utility for detection of cryptococcal antigen in BAL fluid is uncertain, although these specimen types have yielded positive results in
         <em>
          C. neoformans
         </em>
         infection.
        </p>
        <p>
         In contrast with its diagnostic value, the utility of serum or CSF cryptococcal antigen testing in monitoring response to therapy is uncertain. Concordance between changes in titers and clinical or mycologic outcomes is often poor. Titers remain elevated for prolonged periods (months to &gt;2 years) [
         <a href="#rid11">
          11,13
         </a>
         ]. Cryptococcal antigen results should therefore be interpreted in conjunction with the clinical assessment.
        </p>
        <p>
         Cryptococcal antigen testing is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3757.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of Cryptococcus neoformans meningoencephalitis in patients with HIV", section on 'Cryptococcal antigen (CrAg)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2447.html" rel="external">
          "Clinical manifestations and diagnosis of Cryptococcus neoformans meningoencephalitis in patients without HIV", section on 'Cryptococcal antigen'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2421.html" rel="external">
          "Cryptococcus neoformans infection outside the central nervous system", section on 'Cryptococcal antigen'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H644687886">
         <span class="h4">
          Lateral flow assay
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of lateral flow assays (LFAs) for cryptococcal antigen detection have been developed as a rapid test to screen patients for cryptococcosis. The simple dipstick format of these assays uses monoclonal antibodies directed at glucuronoxylomannan to capture cryptococcal antigen of both
         <em>
          C. neoformans
         </em>
         and
         <em>
          C. gattii
         </em>
         . Data from the manufacturers and from two studies examining the performance of the first LFA (IMMY, Immuno-Mycologics, Norman, Oklahoma) on samples from patients with HIV and
         <em>
          C. neoformans
         </em>
         infection indicate sensitivities of 90 to 99.8 percent for serum, 96 to 100 percent for CSF, and 70 to 98 percent for urine [
         <a href="#rid62">
          62-64
         </a>
         ]. LFA results showed good agreement with EIA results [
         <a href="#rid62">
          62,63
         </a>
         ]. As of June 2019, the Immy LFA test has been US Food and Drug Administration (FDA) cleared in the United States and is European Conformity (CE) marked in Europe; other LFA formats have had only limited validation with varying sensitivity and specificity, and none are FDA approved [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
         The LFA is only semiquantitative and titers obtained by this method have not yet been systematically correlated with those obtained by latex agglutination. Sensitivity and specificity of the LFA in the diagnosis of
         <em>
          C. gattii
         </em>
         infection are likely to be similar to that for
         <em>
          C. neoformans
         </em>
         , as indicated by two small studies in which 4 and 10 patients, respectively, with confirmed
         <em>
          C. gattii
         </em>
         infection had positive LFA results [
         <a href="#rid66">
          66,67
         </a>
         ]. However, large studies to evaluate the ability of the assay to detect different
         <em>
          C. gattii
         </em>
         VG types have not yet been performed.
        </p>
        <p>
         The LFA has potential as a point-of-care test to screen patients for
         <em>
          C. gattii
         </em>
         infection, especially in resource-limited regions because it is simple, rapid (10 to 15 minutes), and does not require refrigeration or substantive laboratory infrastructure; costs are $1.25 to $2.50 (USD) per test. Prospective studies are needed to determine the position of the LFA as a screening tool for asymptomatic cryptococcemia.
        </p>
        <p class="headingAnchor" id="H12417232">
         <span class="h3">
          Molecular tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Molecular tests, such as the polymerase chain reaction test, can distinguish between
         <em>
          C. neoformans
         </em>
         and
         <em>
          C. gattii
         </em>
         but are seldom required for diagnosis. However, in the uncommon event that the isolate does not grow or is seen only in histologic sections, molecular methods may be used.
        </p>
        <p>
         Molecular techniques demonstrate good overall sensitivity in identifying
         <em>
          C. gattii
         </em>
         in clinical specimens [
         <a href="#rid58">
          58,61,68,69
         </a>
         ]. A combined
         <em>
          C. neoformans
         </em>
         /
         <em>
          C. gattii
         </em>
         target has been incorporated into the commercial FilmArray meningitis/encephalitis panel (BioFire Diagnostics, Salt Lake City, Utah) for use on CSF specimens. In one study, the correlation between the results of this test and cryptococcal antigen testing was 52 percent; however, the correlation between this test and fungal smear or culture was 92 percent [
         <a href="#rid70">
          70
         </a>
         ]. More extensive evaluation is required to better determine the performance of this test for cryptococcosis.
        </p>
        <p class="headingAnchor" id="H526556839">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of
         <em>
          C. gattii
         </em>
         infection includes cryptococcal infection caused by
         <em>
          C. neoformans
         </em>
         as well as other infectious and noninfectious etiologies. The differential diagnosis varies depending upon the clinical manifestations and host immune status.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Meningitis or meningoencephalitis
         </strong>
         – For patients presenting with meningitis or meningoencephalitis, the differential diagnosis is broad and includes
         <em>
          C. neoformans
         </em>
         , bacteria, and viruses (eg, herpes simplex, arboviruses). (See
         <a class="medical medical_review" href="/z/d/html/1287.html" rel="external">
          "Clinical features and diagnosis of acute bacterial meningitis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1296.html" rel="external">
          "Aseptic meningitis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1284.html" rel="external">
          "Viral encephalitis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mass lesions in the brain
         </strong>
         – For patients with mass lesions in the brain, the differential diagnosis includes cryptococcomas due to
         <em>
          C. neoformans
         </em>
         ; abscesses caused by
         <em>
          Aspergillus
         </em>
         spp,
         <em>
          Nocardia
         </em>
         spp, bacteria, or
         <em>
          Toxoplasma gondii
         </em>
         ; and brain tumors. (See
         <a class="medical medical_review" href="/z/d/html/1297.html" rel="external">
          "Pathogenesis, clinical manifestations, and diagnosis of brain abscess"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5515.html" rel="external">
          "Nocardia infections: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2454.html" rel="external">
          "Epidemiology and clinical manifestations of invasive aspergillosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3710.html" rel="external">
          "Toxoplasmosis in patients with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5180.html" rel="external">
          "Overview of the clinical features and diagnosis of brain tumors in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pneumonia and/or pulmonary nodules or masses
         </strong>
         – For patients with pneumonia and/or pulmonary nodules or masses, the differential diagnosis includes other fungal pathogens (eg,
         <em>
          C. neoformans
         </em>
         ,
         <em>
          Aspergillus
         </em>
         spp,
         <em>
          Histoplasma capsulatum
         </em>
         ), bacterial causes of pneumonia (eg,
         <em>
          Nocardia
         </em>
         spp), and, in some cases, septic emboli, malignancy, or granulomatosis with polyangiitis [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2454.html" rel="external">
          "Epidemiology and clinical manifestations of invasive aspergillosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2450.html" rel="external">
          "Pathogenesis and clinical features of pulmonary histoplasmosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2460.html" rel="external">
          "Primary pulmonary coccidioidal infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6990.html" rel="external">
          "Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5515.html" rel="external">
          "Nocardia infections: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4330.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Respiratory tract involvement"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6986.html" rel="external">
          "Diagnostic evaluation of the incidental pulmonary nodule"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3602131188">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113059.html" rel="external">
          "Society guideline links: Cryptococcosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12417289">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          Cryptococcus gattii
         </em>
         is an important fungal pathogen that is endemic in certain regions including Australia and Papua New Guinea. Since the late 1990s, it has been causing an ongoing outbreak in British Columbia, Canada, and the United States Pacific Northwest. Sporadic cases have been reported in various regions around the world. Infection manifests most often as potentially fatal meningoencephalitis and/or pulmonary disease. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neurologic infection is more common in cases of
         <em>
          C. gattii
         </em>
         infection that occur in endemic areas (eg, Australia), compared with the Vancouver outbreak setting, where pulmonary manifestations were more frequent. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Compared with
         <em>
          Cryptococcus neoformans
         </em>
         ,
         <em>
          C. gattii
         </em>
         is significantly more likely to affect the lungs and to cause large mass lesions (cryptococcomas) in the lungs and/or brain. (See
         <a class="local">
          'Comparison of C. gattii and C. neoformans infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The approach to diagnosis of
         <em>
          C. gattii
         </em>
         infection is generally similar to that for
         <em>
          C. neoformans
         </em>
         infection, although imaging to look for cryptococcomas is more of a priority with
         <em>
          C. gattii
         </em>
         than
         <em>
          C. neoformans
         </em>
         given the propensity of
         <em>
          C. gattii
         </em>
         to cause large cryptococcomas. (See
         <a class="local">
          'Approach to diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients suspected of having
         <em>
          C. gattii
         </em>
         infection (eg, patients residing in an endemic area or an area affected by an outbreak [Pacific Northwest region of North America] presenting with evidence of meningoencephalitis [a headache with or without neck stiffness and/or fever] or pneumonia) should undergo studies for
         <em>
          C. gattii
         </em>
         meningoencephalitis, pneumonia, and cryptococcomas of the brain and lungs. Appropriate studies include funduscopic examination, cerebral imaging, chest imaging, serum cryptococcal antigen testing, and cerebrospinal fluid examination for routine studies as well as opening pressure, cryptococcal antigen, India ink staining, and fungal culture. (See
         <a class="local">
          'Approach to diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We favor testing for underlying HIV infection and for other causes of immunodeficiency (eg, CD4 subsets and immunoglobulin subsets). (See
         <a class="local">
          'Approach to diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Special culture medium is required to identify the organism to the species level and is frequently not performed even in endemic areas. However, identification by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) can also provide species identification, provided species-specific reference spectra are adequately represented in the spectral database. Laboratories that do not distinguish to the species level report all isolates as
         <em>
          C. neoformans
         </em>
         . (See
         <a class="local">
          'Approach to diagnosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Chaturvedi V, Chaturvedi S. Cryptococcus gattii: a resurgent fungal pathogen. Trends Microbiol 2011; 19:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris J, Lockhart S, Chiller T. Cryptococcus gattii: where do we go from here? Med Mycol 2012; 50:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacDougall L, Fyfe M. Emergence of Cryptococcus gattii in a novel environment provides clues to its incubation period. J Clin Microbiol 2006; 44:1851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindberg J, Hagen F, Laursen A, et al. Cryptococcus gattii risk for tourists visiting Vancouver Island, Canada. Emerg Infect Dis 2007; 13:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Georgi A, Schneemann M, Tintelnot K, et al. Cryptococcus gattii meningoencephalitis in an immunocompetent person 13 months after exposure. Infection 2009; 37:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johannson KA, Huston SM, Mody CH, Davidson W. Cryptococcus gattii pneumonia. CMAJ 2012; 184:1387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgan J, McCarthy KM, Gould S, et al. Cryptococcus gattii infection: characteristics and epidemiology of cases identified in a South African province with high HIV seroprevalence, 2002-2004. Clin Infect Dis 2006; 43:1077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steele KT, Thakur R, Nthobatsang R, et al. In-hospital mortality of HIV-infected cryptococcal meningitis patients with C. gattii and C. neoformans infection in Gaborone, Botswana. Med Mycol 2010; 48:1112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Emergence of Cryptococcus gattii-- Pacific Northwest, 2004-2010. MMWR Morb Mortal Wkly Rep 2010; 59:865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris JR, Lockhart SR, Debess E, et al. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis 2011; 53:1188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phillips P, Galanis E, MacDougall L, et al. Longitudinal clinical findings and outcome among patients with Cryptococcus gattii infection in British Columbia. Clin Infect Dis 2015; 60:1368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lizarazo J, Escandón P, Agudelo CI, et al. Retrospective study of the epidemiology and clinical manifestations of Cryptococcus gattii infections in Colombia from 1997-2011. PLoS Negl Trop Dis 2014; 8:e3272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen SC, Slavin MA, Heath CH, et al. Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death. Clin Infect Dis 2012; 55:789.
          </a>
         </li>
         <li class="breakAll">
          Sorrell TC, Chen SC-A, Phillips P, Marr KA. Clinical perspectives on Cryptococcus neoformans and Cryptococcus gattii: implications for diagnosis and management. In: Cryptococcus, Heitman J, Kozel TR, Kwon-Chung KJ, et al (Eds), ASM Press, Washington DC 2011. p.595.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell DH, Sorrell TC, Allworth AM, et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis 1995; 20:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lalloo D, Fisher D, Naraqi S, et al. Cryptococcal meningitis (C. neoformans var. gattii) leading to blindness in previously healthy Melanesian adults in Papua New Guinea. Q J Med 1994; 87:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baddley JW, Chen SC, Huisingh C, et al. MSG07: An International Cohort Study Comparing Epidemiology and Outcomes of Patients With Cryptococcus neoformans or Cryptococcus gattii Infections. Clin Infect Dis 2021; 73:1133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen S, Sorrell T, Nimmo G, et al. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin Infect Dis 2000; 31:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jenney A, Pandithage K, Fisher DA, Currie BJ. Cryptococcus infection in tropical Australia. J Clin Microbiol 2004; 42:3865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galanis E, Macdougall L, Kidd S, et al. Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999-2007. Emerg Infect Dis 2010; 16:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galanis E, Hoang L, Kibsey P, et al. Clinical presentation, diagnosis and management of Cryptococcus gattii cases: Lessons learned from British Columbia. Can J Infect Dis Med Microbiol 2009; 20:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garrett L, Marr K, West S, Allada G. 74-year-old man from the pacific northwest with fever and a lung mass. Chest 2011; 140:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell DH, Sorrell TC. Pancoast's syndrome due to pulmonary infection with Cryptococcus neoformans variety gattii. Clin Infect Dis 1992; 14:1142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 1995; 21:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dora JM, Kelbert S, Deutschendorf C, et al. Cutaneous cryptococccosis due to Cryptococcus gattii in immunocompetent hosts: case report and review. Mycopathologia 2006; 161:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mistry N, Tan K, Shokravi M, Hoang L. Cryptococcus gattii infections with cutaneous involvement. J Cutan Med Surg 2011; 15:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Byrnes EJ 3rd, Li W, Lewit Y, et al. First reported case of Cryptococcus gattii in the Southeastern USA: implications for travel-associated acquisition of an emerging pathogen. PLoS One 2009; 4:e5851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Araújo BS, Bay M, Reichert R, Goldani LZ. Intra-abdominal cryptococcosis by Cryptococcus gattii: case report and review. Mycopathologia 2012; 174:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dall Bello AG, Severo CB, Schio S, Severo LC. First reported case of cellulitis due to Cryptococcus gattii in lung transplantation recipient: a case report. Dermatol Online J 2013; 19:20395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindell RM, Hartman TE, Nadrous HF, Ryu JH. Pulmonary cryptococcosis: CT findings in immunocompetent patients. Radiology 2005; 236:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang CJ, Hwang JJ, Wang TH, et al. Clinical and radiographic presentations of pulmonary cryptococcosis in immunocompetent patients. Scand J Infect Dis 2006; 38:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 2000; 30:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:710.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seaton RA, Verma N, Naraqi S, et al. The effect of corticosteroids on visual loss in Cryptococcus neoformans var. gattii meningitis. Trans R Soc Trop Med Hyg 1997; 91:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen SC, Korman TM, Slavin MA, et al. Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii. Clin Infect Dis 2013; 57:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franco-Paredes C, Womack T, Bohlmeyer T, et al. Management of Cryptococcus gattii meningoencephalitis. Lancet Infect Dis 2015; 15:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park MK, Hospenthal DR, Bennett JE. Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting. Clin Infect Dis 1999; 28:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rex JH, Larsen RA, Dismukes WE, et al. Catastrophic visual loss due to Cryptococcus neoformans meningitis. Medicine (Baltimore) 1993; 72:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andreola C, Ribeiro MP, de Carli CR, et al. Multifocal choroiditis in disseminated Cryptococcus neoformans infection. Am J Ophthalmol 2006; 142:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phillips P, Chapman K, Sharp M, et al. Dexamethasone in Cryptococcus gattii central nervous system infection. Clin Infect Dis 2009; 49:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lane M, McBride J, Archer J. Steroid responsive late deterioration in Cryptococcus neoformans variety gattii meningitis. Neurology 2004; 63:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bicanic T, Meintjes G, Rebe K, et al. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr 2009; 51:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Einsiedel L, Gordon DL, Dyer JR. Paradoxical inflammatory reaction during treatment of Cryptococcus neoformans var. gattii meningitis in an HIV-seronegative woman. Clin Infect Dis 2004; 39:e78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panackal AA, Wuest SC, Lin YC, et al. Paradoxical Immune Responses in Non-HIV Cryptococcal Meningitis. PLoS Pathog 2015; 11:e1004884.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panackal AA, Komori M, Kosa P, et al. Spinal Arachnoiditis as a Complication of Cryptococcal Meningoencephalitis in Non-HIV Previously Healthy Adults. Clin Infect Dis 2017; 64:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xie LX, Chen YS, Liu SY, Shi YX. Pulmonary cryptococcosis: comparison of CT findings in immunocompetent and immunocompromised patients. Acta Radiol 2015; 56:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roebuck DJ, Fisher DA, Currie BJ. Cryptococcosis in HIV negative patients: findings on chest radiography. Thorax 1998; 53:554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baddley JW, Perfect JR, Oster RA, et al. Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease. Eur J Clin Microbiol Infect Dis 2008; 27:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi HW, Chong S, Kim MK, Park IW. Pulmonary cryptococcosis manifesting as diffuse air-space consolidations in an immunocompetent patient. J Thorac Dis 2017; 9:E138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charlier C, Dromer F, Lévêque C, et al. Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. PLoS One 2008; 3:e1950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akins PT, Jian B. The Frozen Brain State of Cryptococcus gattii: A Globe-Trotting, Tropical, Neurotropic Fungus. Neurocrit Care 2019; 30:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacDougall L, Fyfe M, Romney M, et al. Risk factors for Cryptococcus gattii infection, British Columbia, Canada. Emerg Infect Dis 2011; 17:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Browne SK, Burbelo PD, Chetchotisakd P, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med 2012; 367:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen LB, Freeman AF, Yang LM, et al. Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis. J Immunol 2013; 190:3959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen SC, Meyer W, Sorrell TC. Cryptococcus gattii infections. Clin Microbiol Rev 2014; 27:980.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazcano O, Speights VO Jr, Strickler JG, et al. Combined histochemical stains in the differential diagnosis of Cryptococcus neoformans. Mod Pathol 1993; 6:80.
          </a>
         </li>
         <li class="breakAll">
          Diaz MR, Nguyen MH. Diagnostic approach based on capsular antigen, capsule detection, β-glucan and DNA analysis. In: Cryptococcus: From human pathogen to model yeast, Heitman J, Kozel TR, Kwon-Chung KJ, et al (Eds), ASM Press, Washington DC 2011. p.547.
         </li>
         <li class="breakAll">
          Hazen KC, Howell SA. Candida, Cryptococcus, and other yeasts of medical importance. In: Manual of Clinical Microbiology, Murray PR, Barron EJ, Jorgensen JH, et al (Eds), ASM Press, Washington DC 2007. p.762.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Posteraro B, Vella A, Cogliati M, et al. Matrix-assisted laser desorption ionization-time of flight mass spectrometry-based method for discrimination between molecular types of Cryptococcus neoformans and Cryptococcus gattii. J Clin Microbiol 2012; 50:2472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sidrim JJ, Costa AK, Cordeiro RA, et al. Molecular methods for the diagnosis and characterization of Cryptococcus: a review. Can J Microbiol 2010; 56:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindsley MD, Mekha N, Baggett HC, et al. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis 2011; 53:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jarvis JN, Percival A, Bauman S, et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis 2011; 53:1019.
          </a>
         </li>
         <li class="breakAll">
          IMMY CrAg lateral flow assay for the detection of cryptococcal antigen. http://www.immy.com/wp-content/uploads/2012/05/CR2003-CrAg-LFA-PI-US.pdf (Accessed on September 10, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajasingham R, Wake RM, Beyene T, et al. Cryptococcal Meningitis Diagnostics and Screening in the Era of Point-of-Care Laboratory Testing. J Clin Microbiol 2019; 57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McMullan BJ, Halliday C, Sorrell TC, et al. Clinical utility of the cryptococcal antigen lateral flow assay in a diagnostic mycology laboratory. PLoS One 2012; 7:e49541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tintelnot K, Hagen F, Han CO, et al. Pitfalls in Serological Diagnosis of Cryptococcus gattii Infections. Med Mycol 2015; 53:874.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feng X, Fu X, Ling B, et al. Development of a singleplex PCR assay for rapid identification and differentiation of Cryptococcus neoformans var. grubii, Cryptococcus neoformans var. neoformans, Cryptococcus gattii, and hybrids. J Clin Microbiol 2013; 51:1920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feng X, Fu X, Ling B, et al. Rapid differentiation of cryptic species within Cryptococcus gattii by a duplex PCR assay. J Clin Microbiol 2013; 51:3110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liesman RM, Strasburg AP, Heitman AK, et al. Evaluation of a Commercial Multiplex Molecular Panel for Diagnosis of Infectious Meningitis and Encephalitis. J Clin Microbiol 2018; 56.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 85842 Version 20.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21880492" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Cryptococcus gattii: a resurgent fungal pathogen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21939343" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Cryptococcus gattii: where do we go from here?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16672420" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Emergence of Cryptococcus gattii in a novel environment provides clues to its incubation period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17370544" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Cryptococcus gattii risk for tourists visiting Vancouver Island, Canada.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19390780" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Cryptococcus gattii meningoencephalitis in an immunocompetent person 13 months after exposure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22891210" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Cryptococcus gattii pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16983624" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Cryptococcus gattii infection: characteristics and epidemiology of cases identified in a South African province with high HIV seroprevalence, 2002-2004.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20438294" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : In-hospital mortality of HIV-infected cryptococcal meningitis patients with C. gattii and C. neoformans infection in Gaborone, Botswana.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20651641" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Emergence of Cryptococcus gattii-- Pacific Northwest, 2004-2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22016503" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25632012" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Longitudinal clinical findings and outcome among patients with Cryptococcus gattii infection in British Columbia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25411779" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Retrospective study of the epidemiology and clinical manifestations of Cryptococcus gattii infections in Colombia from 1997-2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22670042" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22670042" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7756484" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8041866" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Cryptococcal meningitis (C. neoformans var. gattii) leading to blindness in previously healthy Melanesian adults in Papua New Guinea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33772538" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : MSG07: An International Cohort Study Comparing Epidemiology and Outcomes of Patients With Cryptococcus neoformans or Cryptococcus gattii Infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10987712" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15297551" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Cryptococcus infection in tropical Australia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20113555" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999-2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20190892" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Clinical presentation, diagnosis and management of Cryptococcus gattii cases: Lessons learned from British Columbia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21896527" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : 74-year-old man from the pacific northwest with fever and a lung mass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1600018" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Pancoast's syndrome due to pulmonary infection with Cryptococcus neoformans variety gattii.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7578756" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Clinical and host differences between infections with the two varieties of Cryptococcus neoformans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16552487" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Cutaneous cryptococccosis due to Cryptococcus gattii in immunocompetent hosts: case report and review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21781631" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Cryptococcus gattii infections with cutaneous involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19516904" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : First reported case of Cryptococcus gattii in the Southeastern USA: implications for travel-associated acquisition of an emerging pathogen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22246960" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Intra-abdominal cryptococcosis by Cryptococcus gattii: case report and review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24314772" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : First reported case of cellulitis due to Cryptococcus gattii in lung transplantation recipient: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15987984" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Pulmonary cryptococcosis: CT findings in immunocompetent patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16938733" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Clinical and radiographic presentations of pulmonary cryptococcosis in immunocompetent patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10619732" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10770733" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9093628" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The effect of corticosteroids on visual loss in Cryptococcus neoformans var. gattii meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23697747" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25467646" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Management of Cryptococcus gattii meningoencephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10194090" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8341139" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Catastrophic visual loss due to Cryptococcus neoformans meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16876530" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Multifocal choroiditis in disseminated Cryptococcus neoformans infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19589083" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Dexamethasone in Cryptococcus gattii central nervous system infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15326249" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Steroid responsive late deterioration in Cryptococcus neoformans variety gattii meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19365271" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15486830" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Paradoxical inflammatory reaction during treatment of Cryptococcus neoformans var. gattii meningitis in an HIV-seronegative woman.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26020932" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Paradoxical Immune Responses in Non-HIV Cryptococcal Meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28011613" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Spinal Arachnoiditis as a Complication of Cryptococcal Meningoencephalitis in Non-HIV Previously Healthy Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24757183" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Pulmonary cryptococcosis: comparison of CT findings in immunocompetent and immunocompromised patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9797753" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Cryptococcosis in HIV negative patients: findings on chest radiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18449582" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28275498" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Pulmonary cryptococcosis manifesting as diffuse air-space consolidations in an immunocompetent patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18414656" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29663282" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The Frozen Brain State of Cryptococcus gattii: A Globe-Trotting, Tropical, Neurotropic Fungus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21291588" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Risk factors for Cryptococcus gattii infection, British Columbia, Canada.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22913682" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Adult-onset immunodeficiency in Thailand and Taiwan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23509356" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20047480" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25278580" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Cryptococcus gattii infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7678937" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Combined histochemical stains in the differential diagnosis of Cryptococcus neoformans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7678937" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Combined histochemical stains in the differential diagnosis of Cryptococcus neoformans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7678937" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Combined histochemical stains in the differential diagnosis of Cryptococcus neoformans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22573595" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Matrix-assisted laser desorption ionization-time of flight mass spectrometry-based method for discrimination between molecular types of Cryptococcus neoformans and Cryptococcus gattii.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20657615" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Molecular methods for the diagnosis and characterization of Cryptococcus: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21810743" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21940419" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21940419" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30257903" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Cryptococcal Meningitis Diagnostics and Screening in the Era of Point-of-Care Laboratory Testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23166705" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Clinical utility of the cryptococcal antigen lateral flow assay in a diagnostic mycology laboratory.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26337090" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Pitfalls in Serological Diagnosis of Cryptococcus gattii Infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23536400" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Development of a singleplex PCR assay for rapid identification and differentiation of Cryptococcus neoformans var. grubii, Cryptococcus neoformans var. neoformans, Cryptococcus gattii, and hybrids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23824773" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Rapid differentiation of cryptic species within Cryptococcus gattii by a duplex PCR assay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29436421" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Evaluation of a Commercial Multiplex Molecular Panel for Diagnosis of Infectious Meningitis and Encephalitis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
